The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate
the health and economic outcomes of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive NMIBC. Complete details of ICER’s systematic literature search and protocol, as well as the methodology and model structure for the economic evaluation are available on ICER’s website at

In this report, we present the summary of our findings and highlights of the policy discussion with key stakeholders held at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on November 20, 2020